{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T06:04:39Z","timestamp":1784009079758,"version":"3.55.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy of limus-coated balloons (Limus-DCB) compared with paclitaxel-coated balloons (PCB) in the treatment of coronary artery disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, Embase, Cochrane Library, and Web of Science for randomized controlled trials (RCTs) comparing Limus-DCB with PCB for coronary artery disease from inception to June 2026. Two reviewers independently screened the literature, extracted data, and assessed the risk of bias of the included studies. Meta-analysis was performed using RevMan 5.4.1 software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 10 studies involving 11 RCTs with 1,707 patients and 1,804 treated vessels were included. The meta-analysis showed that the Limus-DCB group was associated with marginally greater in-segment late lumen loss (LLL) (MD\u2009=\u20090.10, 95% CI 0.00\u20130.19,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.04) and marginally smaller in-lesion minimal lumen diameter (MLD) (MD\u2009=\u2009\u22120.10, 95% CI \u22120.19 to 0.00,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.04). There were no significant differences between the two groups in in-lesion LLL, late lumen enlargement (LLE), binary restenosis rate, target lesion failure (TLF), or major adverse cardiovascular events (MACE).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Based on current evidence, compared with PCB, Limus-DCB are associated with less favorable angiographic outcomes in the treatment of coronary artery disease. However, no statistically significant short-term clinical differences were detected between the two groups. Due to the limitations in the quantity and quality of the included studies, these findings need to be verified by more high-quality research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/recorddashboard<\/jats:ext-link>\n                      , identifier CRD420251153751.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1872397","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:37:44Z","timestamp":1784007464000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A meta-analysis of the efficacy of limus-coated balloons vs. paclitaxel-coated balloons for coronary artery disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Shichuan","family":"Li","sequence":"first","affiliation":[{"name":"Department of Cardiology, Chongqing Rongchang District People's Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Chongqing Rongchang District People's Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangbo","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Chongqing Rongchang District People's Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Chongqing Rongchang District People's Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinmei","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Chongqing Rongchang District People\u2019s Hospital","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/s0735-1097(97)00334-3","article-title":"Predictive factors of restenosis after coronary stent placement","volume":"30","author":"Kastrati","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(18)31719-7","article-title":"Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial","volume":"392","author":"Jeger","year":"2018","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1016\/j.jcin.2020.08.035","article-title":"Drug-coated balloon versus drug-eluting stent for small coronary vessel disease: PICCOLETO II randomized clinical trial","volume":"13","author":"Cortese","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1093\/eurheartj\/ehz731","article-title":"Paclitaxel-coated balloons: a safe alternative to drug-eluting stents for coronary in-stent restenosis","volume":"41","author":"Lansky","year":"2020","journal-title":"Eur Heart J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e389","DOI":"10.4244\/EIJ-D-23-00425","article-title":"Biological differences of three paclitaxel- and sirolimus-coated balloons on coronary lesions in a rabbit model","volume":"20","author":"Aihara","year":"2024","journal-title":"EuroIntervention"},{"key":"B6","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.jcin.2024.12.024","article-title":"Sirolimus- vs paclitaxel-coated balloon for the treatment of coronary in-stent restenosis: the SIBLINT-ISR randomized trial","volume":"18","author":"Liu","year":"2025","journal-title":"JACC Cardiovasc Interv"},{"key":"B7","volume-title":"Methodological Standards for the Conduct of new Cochrane Intervention Reviews","author":"Chandler","year":"2013"},{"key":"B8","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Br Med J"},{"key":"B10","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0","author":"Higgins","year":"2011"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e1322","DOI":"10.4244\/EIJ-D-23-00868","article-title":"A randomised trial of sirolimus- versus paclitaxel-coated balloons for de novo coronary lesions","volume":"20","author":"Scheller","year":"2024","journal-title":"EuroIntervention"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1016\/j.jcin.2023.09.026","article-title":"A prospective randomized trial comparing sirolimus-coated balloon with paclitaxel-coated balloon in de novo small vessels","volume":"16","author":"Ninomiya","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"key":"B13","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jcin.2022.01.012","article-title":"Treatment of coronary de novo lesions by a sirolimus- or paclitaxel-coated balloon","volume":"15","author":"Ahmad","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e014677","DOI":"10.1161\/CIRCINTERVENTIONS.124.014677","article-title":"Comparing the efficacy of sirolimus and paclitaxel-eluting balloon catheters in the treatment of coronary in-stent restenosis: a prospective randomized study (TIS 2 study)","volume":"18","author":"Pleva","year":"2025","journal-title":"Circ Cardiovasc Interv"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e806","DOI":"10.4244\/EIJ-D-24-00295","article-title":"Biolimus-coated versus paclitaxel-coated balloons for coronary in-stent restenosis (BIO ASCEND ISR): a randomised, non-inferiority trial","volume":"20","author":"Chen","year":"2024","journal-title":"EuroIntervention"},{"key":"B16","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jcin.2024.11.026","article-title":"Randomized trial of Biolimus DCB for in-stent restenosis: the primary results of the REFORM study","volume":"18","author":"Byrne","year":"2025","journal-title":"JACC Cardiovasc Interv"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e307","DOI":"10.4244\/EIJ-D-24-00742","article-title":"Sirolimus-coated versus paclitaxel-coated balloons for bifurcated coronary lesions in the side branch: the SPACIOUS trial","volume":"21","author":"Zhou","year":"2025","journal-title":"EuroIntervention"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e012305","DOI":"10.1161\/CIRCINTERVENTIONS.122.012305","article-title":"Combined analysis of two parallel randomized trials of sirolimus-coated and paclitaxel-coated balloons in coronary in-stent restenosis lesions","volume":"15","author":"Scheller","year":"2022","journal-title":"Circ Cardiovasc Interv"},{"key":"B19","doi-asserted-by":"publisher","first-page":"10869","DOI":"10.21037\/jtd-2025-1243","article-title":"A prospective randomized open-label trial of sirolimus versus paclitaxel-coated balloons for the side branch of de novo coronary bifurcation lesion","volume":"17","author":"Gao","year":"2025","journal-title":"J Thorac Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jcin.2018.11.040","article-title":"Treatment of coronary drug-eluting stent restenosis by a sirolimus- or paclitaxel-coated balloon","volume":"12","author":"Ali","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"B21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jclinepi.2012.01.012","article-title":"GRADE Guidelines: 12. Preparing summary of findings tables-binary outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jclinepi.2012.08.001","article-title":"GRADE Guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/ccd.31154","article-title":"Paclitaxel-coated versus sirolimus-coated balloon angioplasty for coronary artery disease: a systematic review and meta-analysis","volume":"104","author":"Shin","year":"2024","journal-title":"Catheter Cardiovasc Interv"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.jcin.2024.04.042","article-title":"Outcomes with limus- vs paclitaxel-coated balloons for percutaneous coronary intervention: meta-analysis of randomized controlled trials","volume":"17","author":"Sedhom","year":"2024","journal-title":"JACC Cardiovasc Interv"},{"key":"B25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4244\/AIJ-D-25-00029","article-title":"Head-to-head comparison of limus- versus paclitaxel-coated balloons in the treatment of in-stent restenosis: a meta-analysis","volume":"12","author":"Sagris","year":"2026","journal-title":"AsiaIntervention"},{"key":"B26","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1161\/01.cir.96.2.636","article-title":"Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery","volume":"96","author":"Axel","year":"1997","journal-title":"Circulation"},{"key":"B27","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.bbrc.2010.12.018","article-title":"Paclitaxel stimulates chromosomal fusion and instability in cells with dysfunctional telomeres: implication in multinucleation and chemosensitization","volume":"404","author":"Park","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"B28","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1161\/01.CIR.0000138929.71660.E0","article-title":"Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis","volume":"110","author":"Scheller","year":"2004","journal-title":"Circulation"},{"key":"B29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00392-014-0775-2","article-title":"Local paclitaxel induces late lumen enlargement in coronary arteries after balloon angioplasty","volume":"104","author":"Kleber","year":"2015","journal-title":"Clin Res Cardiol"},{"key":"B30","first-page":"4355","article-title":"Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase","volume":"54","author":"Long","year":"1994","journal-title":"Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1161\/01.cir.104.8.852","article-title":"Bench to bedside: the development of rapamycin and its application to stent restenosis","volume":"104","author":"Marx","year":"2001","journal-title":"Circulation"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.18632\/oncotarget.27554","article-title":"Sirolimus-eluting stents: opposite in vitro effects on the clonogenic cell potential on a long-term exposure","volume":"11","author":"Vasuri","year":"2020","journal-title":"Oncotarget"},{"key":"B33","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2217\/fca-2019-0009","article-title":"Drug-coated balloons for coronary artery disease: current concepts and controversies","volume":"15","author":"Buccheri","year":"2019","journal-title":"Future Cardiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1184816","DOI":"10.3389\/fcvm.2023.1184816","article-title":"Pre-clinical investigation of liquid sirolimus for local drug delivery","volume":"10","author":"Todd","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa061254","article-title":"Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter","volume":"355","author":"Scheller","year":"2006","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"key":"B37","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/eurheartj\/ehi721","article-title":"Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels","volume":"27","author":"Mehilli","year":"2006","journal-title":"Eur Heart J"},{"key":"B38","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jama.295.8.895","article-title":"Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial","volume":"295","author":"Morice","year":"2006","journal-title":"JAMA"},{"key":"B39","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.carrev.2023.06.004","article-title":"Design and rationale of a prospective, randomized, non-inferiority trial to determine the safety and efficacy of the Biolimus A9\u2122 drug coated balloon for the treatment of in-stent restenosis: first-in-man trial (REFORM)","volume":"56","author":"Traynor","year":"2023","journal-title":"Cardiovasc Revasc Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"175","DOI":"10.7150\/thno.7210","article-title":"Nanoparticle drug- and gene-eluting stents for the prevention and treatment of coronary restenosis","volume":"4","author":"Yin","year":"2014","journal-title":"Theranostics"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1872397\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:37:46Z","timestamp":1784007466000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1872397\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":40,"alternative-id":["10.3389\/fcvm.2026.1872397"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1872397","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"article-number":"1872397"}}